MJB Felippe
John Wiley & Sons
e druk, 2016
9781118558874
Equine Clinical Immunology
Specificaties
Gebonden, 344 blz.
|
Engels
John Wiley & Sons |
e druk, 2016
ISBN13: 9781118558874
Rubricering
Verwachte levertijd ongeveer 9 werkdagen
Samenvatting
Equine Clinical Immunology offers comprehensive information on equine immunological disorders.
Provides a complete, equine–specific reference on clinical immunology
Focuses on clinically relevant information for the diagnosis and treatment of horses with immune disorders
Illustrates the concepts discussed using drawings, photographs, and tables
Presents key concepts, clinical assessment information, and treatment approaches in text boxes for ease of use
Offers a practical, clinically oriented approach ideal for equine specialists
Specificaties
Inhoudsopgave
<p>Contributors, ix</p>
<p>Preface, xi</p>
<p>1 The Immune System, 1<br />M. Julia B. Felippe</p>
<p>1.1 Definition, 1</p>
<p>1.2 The organs of the immune system, 1</p>
<p>1.3 The immune cells and soluble molecules, 2</p>
<p>1.4 B and T cell activation in lymphoid tissues, 6</p>
<p>1.5 When the immune response goes wrong, 9</p>
<p>References, 10</p>
<p>2 The Immune System of the Young Horse, 11<br />Rebecca L. Tallmadge</p>
<p>2.1 Definition, 11</p>
<p>2.2 Equine immune system development, 11</p>
<p>2.3 Unique susceptibilities and disorders of young horses, 16</p>
<p>2.4 Vaccinology teaches about neonatal immunity, 18</p>
<p>References, 18</p>
<p>3 The Immune System of the Older Horse, 23<br />Amanda A. Adams and David W. Horohov</p>
<p>3.1 Definition, 23</p>
<p>3.2 Clinical conditions associated with aging, 23</p>
<p>3.3 Immunosenescence and vaccination, 23</p>
<p>3.4 Nutrition in enhancing immunity in the old horse, 26</p>
<p>3.5 Conclusion, 27</p>
<p>References, 27</p>
<p>4 Anaphylaxis, 31<br />Rolfe M. Radcliffe</p>
<p>4.1 Definition, 31</p>
<p>4.2 Signalment and clinical signs, 31</p>
<p>4.3 Immunologic mechanisms and etiologic associations, 32</p>
<p>4.4 Diagnostics, 33</p>
<p>4.5 Treatment, 34</p>
<p>4.6 Prevention, 36</p>
<p>4.7 Prognosis and clinical outcomes, 37</p>
<p>References, 37</p>
<p>5 Allergy, 39<br />Bettina Wagner</p>
<p>5.1 Definition, 39</p>
<p>5.2 Culicoides hypersensitivity, 39</p>
<p>5.3 Urticaria, 43</p>
<p>5.4 Recurrent airway obstruction, 44</p>
<p>References, 44</p>
<p>6 Immune–Mediated Cytopenias, 47<br />Thomas J. Divers</p>
<p>6.1 Definition, 47</p>
<p>6.2 Immune–mediated hemolytic anemia, 47</p>
<p>6.3 Immune–mediated thrombocytopenia, 50</p>
<p>6.4 Immune–mediated neutropenia, 53</p>
<p>References, 54</p>
<p>7 Bullous Diseases of the Skin and Mucosa, 55<br />Jeanine Peters–Kennedy and Rebecca E. Ruby</p>
<p>7.1 Definition, 55</p>
<p>7.2 Immune–mediated bullous dermatoses, 55</p>
<p>7.3 Pemphigus complex, 57</p>
<p>7.4 Cutaneous adverse drug reactions, 61</p>
<p>7.5 Erythema multiforme, 62</p>
<p>7.6 Lupus erythematosus, 64</p>
<p>References, 65</p>
<p>8 Serum Sickness, 69<br />Lais R.R. Costa</p>
<p>8.1 Definition, 69</p>
<p>8.2 Signalment and clinical signs, 69</p>
<p>8.3 Immunologic mechanisms and etiologic associations, 69</p>
<p>8.4 Diagnostics, 71</p>
<p>8.5 Treatment and prevention, 71</p>
<p>References, 72</p>
<p>9 Vasculitis, 73<br />James S. W. Prutton and Nicola Pusterla</p>
<p>9.1 Definition, 73</p>
<p>9.2 Signalment and clinical signs, 73</p>
<p>9.3 Immunologic mechanisms and etiologic associations, 73</p>
<p>9.4 Diagnostics, 75</p>
<p>9.5 Treatment, 75</p>
<p>9.6 Thrombophlebitis, 75</p>
<p>9.7 Pastern and cannon leukocytoclastic vasculitis, 76</p>
<p>9.8 Drug–induced vasculitis, 76</p>
<p>9.9 Photo–activated vasculitis (photodynamic drugs), 77</p>
<p>9.10 Strongylus vulgaris, 77</p>
<p>9.11 Equine granulocytic anaplasmosis, 77</p>
<p>9.12 Equine viral arteritis, 78</p>
<p>9.13 Equine herpesvirus–1, 78</p>
<p>9.14 African horse sickness, 78</p>
<p>References, 79</p>
<p>10 Purpura Hemorrhagica, 83<br />Laszlo M. Hunyadi and Nicola Pusterla</p>
<p>10.1 Definition, 83</p>
<p>10.2 Signalment and clinical signs, 83</p>
<p>10.3 Immunologic mechanisms and etiologic associations, 83</p>
<p>10.4 Diagnostics, 84</p>
<p>10.5 Treatment and prevention, 85</p>
<p>References, 86</p>
<p>11 Glomerulonephritis, 87<br />M. Julia B. Felippe</p>
<p>11.1 Definition, 87</p>
<p>11.2 Signalment and clinical signs, 87</p>
<p>11.3 Immunologic mechanisms and etiologic associations, 87</p>
<p>11.4 Diagnostics, 88</p>
<p>11.5 Treatment and prognosis, 88</p>
<p>References, 88</p>
<p>12 Inflammatory and Immune–Mediated Muscle Disorders, 91<br />Sian Durward–Akhurst and Stephanie J. Valberg</p>
<p>12.1 Definition, 91</p>
<p>12.2 Infarctive purpura hemorrhagica, 91</p>
<p>12.3 Rhabdomyolysis associated with Streptococcus equi, 93</p>
<p>12.4 Immune–mediated myositis in Quarter Horse–related breeds, 94</p>
<p>12.5 Systemic calcinosis, 96</p>
<p>12.6 Uncharacterized immune–mediated and inflammatory myopathies, 97</p>
<p>12.7 Sarcocystis myositis, 97</p>
<p>References, 98</p>
<p>13 Granulomatous Diseases, 101<br />Lais R.R. Costa</p>
<p>13.1 Definition, 101</p>
<p>13.2 Signalment and clinical signs, 101</p>
<p>13.3 Immunologic mechanisms and etiologic associations, 101</p>
<p>13.4 Diagnostics, 104</p>
<p>13.5 Treatment and prevention, 105</p>
<p>13.6 Types of cell–mediated hypersensitivity reactions, 105</p>
<p>References, 110</p>
<p>14 Chronic Inflammatory Bowel Disease, 113<br />Gillian A. Perkins</p>
<p>14.1 Definition, 113</p>
<p>14.2 Signalment and clinical signs, 113</p>
<p>14.3 Immunologic mechanisms and etiologic associations, 113</p>
<p>14.4 Diagnostics, 115</p>
<p>14.5 Treatment and prognosis, 116</p>
<p>References, 117</p>
<p>15 Recurrent Uveitis, 121<br />Brian C. Gilger</p>
<p>15.1 Definition, 121</p>
<p>15.2 Signalment and clinical signs, 121</p>
<p>15.3 Immunologic mechanisms and etiologic associations, 121</p>
<p>15.4 Diagnostics, 123</p>
<p>15.5 Treatment and prevention, 124</p>
<p>15.6 Prognosis and clinical outcomes, 124</p>
<p>References, 125</p>
<p>16 Recurrent Airway Obstruction and Summer Pasture–Associated Obstructive Pulmonary Disease, 127<br />Michela Bullone and Jean–Pierre Lavoie</p>
<p>16.1 Definition, 127</p>
<p>16.2 Signalment and clinical signs, 127</p>
<p>16.3 Immunologic mechanisms and etiologic associations, 128</p>
<p>16.4 Diagnostics, 134</p>
<p>16.5 Treatments and prevention, 136</p>
<p>References, 137</p>
<p>17 Inflammatory Airway Disease, 145<br />Mathilde Leclère and Jean–Pierre Lavoie</p>
<p>17.1 Definition, 145</p>
<p>17.2 Signalment and clinical signs, 145</p>
<p>17.3 Immunologic mechanisms and etiologic associations, 145</p>
<p>17.4 Types of bronchoalveolar lavage fluid inflammation and cytokine profile, 147</p>
<p>17.5 Links between IAD and heaves, 148</p>
<p>17.6 Links between IAD and EIPH, 148</p>
<p>17.7 Diagnostics, 148</p>
<p>17.8 Treatment and prevention, 149</p>
<p>17.9 Prognosis and clinical outcomes, 150</p>
<p>References, 150</p>
<p>18 Inflammation, Endotoxemia and Systemic Inflammatory Response Syndrome, 153<br />Erin L. McConachie and Kelsey A. Hart</p>
<p>18.1 Definition, 153</p>
<p>18.2 Signalment and clinical signs, 154</p>
<p>18.3 Immunologic mechanisms and etiologic associations, 155</p>
<p>18.4 Multi–systemic response triggered by inflammatory mediators, 157</p>
<p>18.5 Diagnostics, 160</p>
<p>18.6 Treatment, 162</p>
<p>18.7 Prognosis and clinical outcome, 166</p>
<p>References, 166</p>
<p>19 Leukemia, 173<br />Tracy Stokol</p>
<p>19.1 Definition, 173</p>
<p>19.2 Classification of leukemias, 173</p>
<p>19.3 Specialized diagnostic techniques for leukemia, 173</p>
<p>19.4 Chronic leukemia, 175</p>
<p>19.5 Acute leukemia, 177</p>
<p>References, 179</p>
<p>20 Lymphoma, 181<br />SallyAnne L. Ness</p>
<p>20.1 Definition, 181</p>
<p>20.2 Signalment and clinical signs, 181</p>
<p>20.3 Forms of equine lymphoma, 182</p>
<p>20.4 Immunologic mechanisms and etiologic associations, 183</p>
<p>20.5 Diagnostics, 183</p>
<p>20.6 Classification of lymphomas, 185</p>
<p>20.7 Prognosis and treatment, 186</p>
<p>20.8 Monitoring, 189</p>
<p>References, 189</p>
<p>21 Immunodeficiencies, 193<br />M. Julia B. Felippe</p>
<p>21.1 Definition, 193</p>
<p>21.2 Classification of immunodeficiencies, 194</p>
<p>References, 202</p>
<p>22 Immunologic Testing, 205<br />M. Julia B. Felippe</p>
<p>22.1 Definition, 205</p>
<p>22.2 Types of immunologic testing, 205</p>
<p>References, 211</p>
<p>23 Non–steroidal Anti–inflammatories, 213<br />Michelle H. Barton</p>
<p>23.1 Definition, 213</p>
<p>23.2 Non–steroidal anti–inflammatory drugs, 213</p>
<p>References, 228</p>
<p>24 Immunosuppressive Therapy, 237<br />M. Julia B. Felippe</p>
<p>24.1 Definition, 237</p>
<p>24.2 Types of immunosuppressive drugs, 237</p>
<p>References, 240</p>
<p>25 Immunomodulators, 243<br />Elizabeth G. Davis</p>
<p>25.1 Definition, 243</p>
<p>25.2 Immunologic mechanisms, 243</p>
<p>25.3 Commercially available immunostimulants for use in horses, 244</p>
<p>References, 249</p>
<p>26 Immunoglobulin Therapy, 251<br />Elizabeth G. Davis</p>
<p>26.1 Definition, 251</p>
<p>26.2 Immunologic mechanisms, 251</p>
<p>References, 254</p>
<p>27 Plasmapheresis, 257<br />Nathan M. Slovis</p>
<p>27.1 Definition, 257</p>
<p>27.2 Methods for preparing plasma products, 257</p>
<p>27.3 Apheresis, 258</p>
<p>27.4 Therapeutic plasmapheresis, 258</p>
<p>27.5 Complications of therapeutic plasmapheresis, 260</p>
<p>References, 260</p>
<p>28 Principles of Vaccination, 263<br />Noah D. Cohen and Angela I. Bordin</p>
<p>28.1 Definition, 263</p>
<p>28.2 Efficacy and effectiveness of vaccines, 263</p>
<p>28.3 Safety of vaccines, 271</p>
<p>28.4 Key knowledge–gaps in equine vaccinology, 273</p>
<p>28.5 Protocols for vaccination, 275</p>
<p>References, 276</p>
<p>29 Types of Vaccines, 279<br />Angela I. Bordin and Noah D. Cohen</p>
<p>29.1 Definition, 279</p>
<p>29.2 Immunologic mechanisms, 279</p>
<p>29.3 Immune responses to vaccination, 282</p>
<p>29.4 Routes of vaccination, 284</p>
<p>29.5 Adjuvants and vaccine delivery systems, 285</p>
<p>29.6 Important diseases with unavailable effective vaccines, 285</p>
<p>References, 286</p>
<p>30 Transplantation Immunology, 289<br />Rebecca L. Tallmadge</p>
<p>30.1 Definition, 289</p>
<p>30.2 Equine MHC genes: genomic organization and variation, 289</p>
<p>30.3 Determining equine MHC haplotypes, 290</p>
<p>30.4 Immunosuppression and engraftment, 291</p>
<p>30.5 Graft rejection, 292</p>
<p>30.6 Current transplantation applications, 293</p>
<p>References, 294</p>
<p>31 Mesenchymal Stem Cell Therapy, 297<br />Gerlinde R. Van de Walle, Catharina De Schauwer and Lisa A. Fortier</p>
<p>31.1 Definition, 297</p>
<p>31.2 Regenerative functions of mesenchymal stem cells, 297</p>
<p>31.3 Immunologic mechanisms and associations, 298</p>
<p>31.4 Sources of equine mesenchymal stem cells, 299</p>
<p>31.5 Characterization of equine mesenchymal stem cells, 300</p>
<p>31.6 Applications of equine mesenchymal stem cells in equine regenerative medicine, 302</p>
<p>References, 306</p>
<p>32 Hematopoietic Stem Cell Transplantation, 311<br />M. Julia B. Felippe</p>
<p>32.1 Definition, 311</p>
<p>32.2 Hematopoietic stem cell sources, 311</p>
<p>32.3 Pre–transplantation conditioning, 313</p>
<p>32.4 Post–transplantation immunosuppression, 313</p>
<p>32.5 Hematopoietic stem cell transplantation in the horse, 313</p>
<p>References, 315</p>
<p>Index, 317</p>
<p>Preface, xi</p>
<p>1 The Immune System, 1<br />M. Julia B. Felippe</p>
<p>1.1 Definition, 1</p>
<p>1.2 The organs of the immune system, 1</p>
<p>1.3 The immune cells and soluble molecules, 2</p>
<p>1.4 B and T cell activation in lymphoid tissues, 6</p>
<p>1.5 When the immune response goes wrong, 9</p>
<p>References, 10</p>
<p>2 The Immune System of the Young Horse, 11<br />Rebecca L. Tallmadge</p>
<p>2.1 Definition, 11</p>
<p>2.2 Equine immune system development, 11</p>
<p>2.3 Unique susceptibilities and disorders of young horses, 16</p>
<p>2.4 Vaccinology teaches about neonatal immunity, 18</p>
<p>References, 18</p>
<p>3 The Immune System of the Older Horse, 23<br />Amanda A. Adams and David W. Horohov</p>
<p>3.1 Definition, 23</p>
<p>3.2 Clinical conditions associated with aging, 23</p>
<p>3.3 Immunosenescence and vaccination, 23</p>
<p>3.4 Nutrition in enhancing immunity in the old horse, 26</p>
<p>3.5 Conclusion, 27</p>
<p>References, 27</p>
<p>4 Anaphylaxis, 31<br />Rolfe M. Radcliffe</p>
<p>4.1 Definition, 31</p>
<p>4.2 Signalment and clinical signs, 31</p>
<p>4.3 Immunologic mechanisms and etiologic associations, 32</p>
<p>4.4 Diagnostics, 33</p>
<p>4.5 Treatment, 34</p>
<p>4.6 Prevention, 36</p>
<p>4.7 Prognosis and clinical outcomes, 37</p>
<p>References, 37</p>
<p>5 Allergy, 39<br />Bettina Wagner</p>
<p>5.1 Definition, 39</p>
<p>5.2 Culicoides hypersensitivity, 39</p>
<p>5.3 Urticaria, 43</p>
<p>5.4 Recurrent airway obstruction, 44</p>
<p>References, 44</p>
<p>6 Immune–Mediated Cytopenias, 47<br />Thomas J. Divers</p>
<p>6.1 Definition, 47</p>
<p>6.2 Immune–mediated hemolytic anemia, 47</p>
<p>6.3 Immune–mediated thrombocytopenia, 50</p>
<p>6.4 Immune–mediated neutropenia, 53</p>
<p>References, 54</p>
<p>7 Bullous Diseases of the Skin and Mucosa, 55<br />Jeanine Peters–Kennedy and Rebecca E. Ruby</p>
<p>7.1 Definition, 55</p>
<p>7.2 Immune–mediated bullous dermatoses, 55</p>
<p>7.3 Pemphigus complex, 57</p>
<p>7.4 Cutaneous adverse drug reactions, 61</p>
<p>7.5 Erythema multiforme, 62</p>
<p>7.6 Lupus erythematosus, 64</p>
<p>References, 65</p>
<p>8 Serum Sickness, 69<br />Lais R.R. Costa</p>
<p>8.1 Definition, 69</p>
<p>8.2 Signalment and clinical signs, 69</p>
<p>8.3 Immunologic mechanisms and etiologic associations, 69</p>
<p>8.4 Diagnostics, 71</p>
<p>8.5 Treatment and prevention, 71</p>
<p>References, 72</p>
<p>9 Vasculitis, 73<br />James S. W. Prutton and Nicola Pusterla</p>
<p>9.1 Definition, 73</p>
<p>9.2 Signalment and clinical signs, 73</p>
<p>9.3 Immunologic mechanisms and etiologic associations, 73</p>
<p>9.4 Diagnostics, 75</p>
<p>9.5 Treatment, 75</p>
<p>9.6 Thrombophlebitis, 75</p>
<p>9.7 Pastern and cannon leukocytoclastic vasculitis, 76</p>
<p>9.8 Drug–induced vasculitis, 76</p>
<p>9.9 Photo–activated vasculitis (photodynamic drugs), 77</p>
<p>9.10 Strongylus vulgaris, 77</p>
<p>9.11 Equine granulocytic anaplasmosis, 77</p>
<p>9.12 Equine viral arteritis, 78</p>
<p>9.13 Equine herpesvirus–1, 78</p>
<p>9.14 African horse sickness, 78</p>
<p>References, 79</p>
<p>10 Purpura Hemorrhagica, 83<br />Laszlo M. Hunyadi and Nicola Pusterla</p>
<p>10.1 Definition, 83</p>
<p>10.2 Signalment and clinical signs, 83</p>
<p>10.3 Immunologic mechanisms and etiologic associations, 83</p>
<p>10.4 Diagnostics, 84</p>
<p>10.5 Treatment and prevention, 85</p>
<p>References, 86</p>
<p>11 Glomerulonephritis, 87<br />M. Julia B. Felippe</p>
<p>11.1 Definition, 87</p>
<p>11.2 Signalment and clinical signs, 87</p>
<p>11.3 Immunologic mechanisms and etiologic associations, 87</p>
<p>11.4 Diagnostics, 88</p>
<p>11.5 Treatment and prognosis, 88</p>
<p>References, 88</p>
<p>12 Inflammatory and Immune–Mediated Muscle Disorders, 91<br />Sian Durward–Akhurst and Stephanie J. Valberg</p>
<p>12.1 Definition, 91</p>
<p>12.2 Infarctive purpura hemorrhagica, 91</p>
<p>12.3 Rhabdomyolysis associated with Streptococcus equi, 93</p>
<p>12.4 Immune–mediated myositis in Quarter Horse–related breeds, 94</p>
<p>12.5 Systemic calcinosis, 96</p>
<p>12.6 Uncharacterized immune–mediated and inflammatory myopathies, 97</p>
<p>12.7 Sarcocystis myositis, 97</p>
<p>References, 98</p>
<p>13 Granulomatous Diseases, 101<br />Lais R.R. Costa</p>
<p>13.1 Definition, 101</p>
<p>13.2 Signalment and clinical signs, 101</p>
<p>13.3 Immunologic mechanisms and etiologic associations, 101</p>
<p>13.4 Diagnostics, 104</p>
<p>13.5 Treatment and prevention, 105</p>
<p>13.6 Types of cell–mediated hypersensitivity reactions, 105</p>
<p>References, 110</p>
<p>14 Chronic Inflammatory Bowel Disease, 113<br />Gillian A. Perkins</p>
<p>14.1 Definition, 113</p>
<p>14.2 Signalment and clinical signs, 113</p>
<p>14.3 Immunologic mechanisms and etiologic associations, 113</p>
<p>14.4 Diagnostics, 115</p>
<p>14.5 Treatment and prognosis, 116</p>
<p>References, 117</p>
<p>15 Recurrent Uveitis, 121<br />Brian C. Gilger</p>
<p>15.1 Definition, 121</p>
<p>15.2 Signalment and clinical signs, 121</p>
<p>15.3 Immunologic mechanisms and etiologic associations, 121</p>
<p>15.4 Diagnostics, 123</p>
<p>15.5 Treatment and prevention, 124</p>
<p>15.6 Prognosis and clinical outcomes, 124</p>
<p>References, 125</p>
<p>16 Recurrent Airway Obstruction and Summer Pasture–Associated Obstructive Pulmonary Disease, 127<br />Michela Bullone and Jean–Pierre Lavoie</p>
<p>16.1 Definition, 127</p>
<p>16.2 Signalment and clinical signs, 127</p>
<p>16.3 Immunologic mechanisms and etiologic associations, 128</p>
<p>16.4 Diagnostics, 134</p>
<p>16.5 Treatments and prevention, 136</p>
<p>References, 137</p>
<p>17 Inflammatory Airway Disease, 145<br />Mathilde Leclère and Jean–Pierre Lavoie</p>
<p>17.1 Definition, 145</p>
<p>17.2 Signalment and clinical signs, 145</p>
<p>17.3 Immunologic mechanisms and etiologic associations, 145</p>
<p>17.4 Types of bronchoalveolar lavage fluid inflammation and cytokine profile, 147</p>
<p>17.5 Links between IAD and heaves, 148</p>
<p>17.6 Links between IAD and EIPH, 148</p>
<p>17.7 Diagnostics, 148</p>
<p>17.8 Treatment and prevention, 149</p>
<p>17.9 Prognosis and clinical outcomes, 150</p>
<p>References, 150</p>
<p>18 Inflammation, Endotoxemia and Systemic Inflammatory Response Syndrome, 153<br />Erin L. McConachie and Kelsey A. Hart</p>
<p>18.1 Definition, 153</p>
<p>18.2 Signalment and clinical signs, 154</p>
<p>18.3 Immunologic mechanisms and etiologic associations, 155</p>
<p>18.4 Multi–systemic response triggered by inflammatory mediators, 157</p>
<p>18.5 Diagnostics, 160</p>
<p>18.6 Treatment, 162</p>
<p>18.7 Prognosis and clinical outcome, 166</p>
<p>References, 166</p>
<p>19 Leukemia, 173<br />Tracy Stokol</p>
<p>19.1 Definition, 173</p>
<p>19.2 Classification of leukemias, 173</p>
<p>19.3 Specialized diagnostic techniques for leukemia, 173</p>
<p>19.4 Chronic leukemia, 175</p>
<p>19.5 Acute leukemia, 177</p>
<p>References, 179</p>
<p>20 Lymphoma, 181<br />SallyAnne L. Ness</p>
<p>20.1 Definition, 181</p>
<p>20.2 Signalment and clinical signs, 181</p>
<p>20.3 Forms of equine lymphoma, 182</p>
<p>20.4 Immunologic mechanisms and etiologic associations, 183</p>
<p>20.5 Diagnostics, 183</p>
<p>20.6 Classification of lymphomas, 185</p>
<p>20.7 Prognosis and treatment, 186</p>
<p>20.8 Monitoring, 189</p>
<p>References, 189</p>
<p>21 Immunodeficiencies, 193<br />M. Julia B. Felippe</p>
<p>21.1 Definition, 193</p>
<p>21.2 Classification of immunodeficiencies, 194</p>
<p>References, 202</p>
<p>22 Immunologic Testing, 205<br />M. Julia B. Felippe</p>
<p>22.1 Definition, 205</p>
<p>22.2 Types of immunologic testing, 205</p>
<p>References, 211</p>
<p>23 Non–steroidal Anti–inflammatories, 213<br />Michelle H. Barton</p>
<p>23.1 Definition, 213</p>
<p>23.2 Non–steroidal anti–inflammatory drugs, 213</p>
<p>References, 228</p>
<p>24 Immunosuppressive Therapy, 237<br />M. Julia B. Felippe</p>
<p>24.1 Definition, 237</p>
<p>24.2 Types of immunosuppressive drugs, 237</p>
<p>References, 240</p>
<p>25 Immunomodulators, 243<br />Elizabeth G. Davis</p>
<p>25.1 Definition, 243</p>
<p>25.2 Immunologic mechanisms, 243</p>
<p>25.3 Commercially available immunostimulants for use in horses, 244</p>
<p>References, 249</p>
<p>26 Immunoglobulin Therapy, 251<br />Elizabeth G. Davis</p>
<p>26.1 Definition, 251</p>
<p>26.2 Immunologic mechanisms, 251</p>
<p>References, 254</p>
<p>27 Plasmapheresis, 257<br />Nathan M. Slovis</p>
<p>27.1 Definition, 257</p>
<p>27.2 Methods for preparing plasma products, 257</p>
<p>27.3 Apheresis, 258</p>
<p>27.4 Therapeutic plasmapheresis, 258</p>
<p>27.5 Complications of therapeutic plasmapheresis, 260</p>
<p>References, 260</p>
<p>28 Principles of Vaccination, 263<br />Noah D. Cohen and Angela I. Bordin</p>
<p>28.1 Definition, 263</p>
<p>28.2 Efficacy and effectiveness of vaccines, 263</p>
<p>28.3 Safety of vaccines, 271</p>
<p>28.4 Key knowledge–gaps in equine vaccinology, 273</p>
<p>28.5 Protocols for vaccination, 275</p>
<p>References, 276</p>
<p>29 Types of Vaccines, 279<br />Angela I. Bordin and Noah D. Cohen</p>
<p>29.1 Definition, 279</p>
<p>29.2 Immunologic mechanisms, 279</p>
<p>29.3 Immune responses to vaccination, 282</p>
<p>29.4 Routes of vaccination, 284</p>
<p>29.5 Adjuvants and vaccine delivery systems, 285</p>
<p>29.6 Important diseases with unavailable effective vaccines, 285</p>
<p>References, 286</p>
<p>30 Transplantation Immunology, 289<br />Rebecca L. Tallmadge</p>
<p>30.1 Definition, 289</p>
<p>30.2 Equine MHC genes: genomic organization and variation, 289</p>
<p>30.3 Determining equine MHC haplotypes, 290</p>
<p>30.4 Immunosuppression and engraftment, 291</p>
<p>30.5 Graft rejection, 292</p>
<p>30.6 Current transplantation applications, 293</p>
<p>References, 294</p>
<p>31 Mesenchymal Stem Cell Therapy, 297<br />Gerlinde R. Van de Walle, Catharina De Schauwer and Lisa A. Fortier</p>
<p>31.1 Definition, 297</p>
<p>31.2 Regenerative functions of mesenchymal stem cells, 297</p>
<p>31.3 Immunologic mechanisms and associations, 298</p>
<p>31.4 Sources of equine mesenchymal stem cells, 299</p>
<p>31.5 Characterization of equine mesenchymal stem cells, 300</p>
<p>31.6 Applications of equine mesenchymal stem cells in equine regenerative medicine, 302</p>
<p>References, 306</p>
<p>32 Hematopoietic Stem Cell Transplantation, 311<br />M. Julia B. Felippe</p>
<p>32.1 Definition, 311</p>
<p>32.2 Hematopoietic stem cell sources, 311</p>
<p>32.3 Pre–transplantation conditioning, 313</p>
<p>32.4 Post–transplantation immunosuppression, 313</p>
<p>32.5 Hematopoietic stem cell transplantation in the horse, 313</p>
<p>References, 315</p>
<p>Index, 317</p>